Factors impacting the combination of topical corticosteroid therapies for psoriasis: perspectives from the international psoriasis council

Corticosteroids are the mainstay of topical therapies for the treatment of mild to moderate psoriasis. Selection of vehicle, concentrations of corticosteroid and coadministered medications, and frequency of administration are critical factors that enhance bioavailability of topical corticosteroids....

Full description

Saved in:
Bibliographic Details
Published in:Journal of the European Academy of Dermatology and Venereology 2011-10, Vol.25 (10), p.1130-1139
Main Authors: van de Kerkhof, P.C.M., Kragballe, K., Segaert, S., Lebwohl, M.
Format: Article
Language:English
Subjects:
Administration, Topical
Adrenal Cortex Hormones - administration & dosage
Adrenal Cortex Hormones - pharmacokinetics
Adrenal Cortex Hormones - therapeutic use
Atrophy
Bioavailability
Biological Availability
Corticoids
Dose-Response Relationship, Drug
Drug Administration Schedule
Drug Therapy, Combination
Foams
Humans
Psoriasis
Psoriasis - drug therapy
Salicylic acid
Side effects
tazarotene
Vitamin D
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Corticosteroids are the mainstay of topical therapies for the treatment of mild to moderate psoriasis. Selection of vehicle, concentrations of corticosteroid and coadministered medications, and frequency of administration are critical factors that enhance bioavailability of topical corticosteroids. Topical corticosteroids are commonly used as polytherapy and combination therapy with other agents, such as salicylic acid, vitamin D analogues and tazarotene. Combinations are selected for the ability to enhance efficacy while minimizing corticosteroid‐related side‐effects, such as cutaneous atrophy. New, innovative products such as sprays, foams and nail lacquers provide opportunities to tailor treatment for individuals, which promotes patient adherence to medications. This review covers features of topical corticosteroid formulations that affect bioavailability, efficacy and safety when used as monotherapy and in combination with other agents for the treatment of mild to moderate psoriasis.
ISSN:0926-9959
1468-3083
DOI:10.1111/j.1468-3083.2011.04113.x